11:17 AM EDT, 07/19/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Friday that the European Medicines Agency has validated its type 2 variation application for Opdivo plus Yervoy as a potential first-line treatment for adult patients with unresectable or advanced hepatocellular carcinoma.

The application was based on results from a late-stage trial showing improved survival with the combination compared with lenvatinib or sorafenib, the drugmaker said. Hepatocellular carcinoma is the most common type of primary liver cancer.

The application validation confirms the submission is complete and begins the EMA's centralized procedure review, the firm said.

Price: 41.67, Change: -0.72, Percent Change: -1.70